1 not yet recruiting, 1 recruiting. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Elranatamab: new trials by email Literature Review of Elranatamab trials Research Report on Elranatamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments Elranatamab - Relapsed/Refractory Multiple Myeloma, Multiple Myeloma | Phase 4 | Not yet recruiting | Pfizer | 75 | 2026-10-22 | 2026-10-19 |
| Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) Elranatamab - Multiple Myeloma | Phase 4 | Recruiting | Pfizer | 80 | 2023-10-03 | 2026-07-01 |
Multiple Myeloma (2) · Neoplasms, Plasma Cell (1)
Pfizer (2)
Australia (1) · Canada (1) · China (1) · Japan (1) · Spain (1) · Taiwan (1) · United States (1)
2023 (1)